BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xcyte Therapies, Inc. Shutting Down Seattle Operations


12/16/2005 1:20:08 PM

Troubled biotech company Xcyte Therapies Inc. said it has reached two separate agreements that result in the closure of the company's facilities in Seattle. Seattle-based Xcyte sold its intellectual property and accumulated clinical data relating to its T-cell expansion technology to Carlsbad, Calif.-based Invitrogen Inc. (NASDAQ: IVGN) for $5 million in cash and possible future payments. Xcyte had stopped all clinical trials earlier this year, though six trials had been conducted on Xcellerated T-Cells as a cancer treatment. Separately, Xcyte agreed to merge with Cyclacel Group PLC, a private biotech company based in Scotland. The merged company will be called Cyclacel Pharmaceuticals Inc. and be based in Short Hills, N.J. All facilities in Seattle will close and the research facilities will be located in the United Kingdom. Cyclacel shareholders will own 80 percent of the merged company, while former Xcyte shareholders will hold the balance, according to a news release. The newly merged entity will build upon Cyclacel's cell cycle biology, which has resulted in a portfolio of three orally available, mechanism-targeted drugs that modulate the cancer cell cycle. Those drug candidates are all in early to midstage clinical trials. Xcyte's decline has been coming for some time.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES